Literature DB >> 8395198

Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

P Omvik1, P Lund-Johansen.   

Abstract

Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure. Antihypertensive agents may, therefore, reduce blood pressure through widely different actions and, at the same time, elicit counterregulatory responses. This is a review of the long-term hemodynamic effects at rest as well as during exercise of nine relatively new antihypertensive compounds: a beta-blocker (epanolol), an alpha-receptor blocker (doxazosin), two double-acting compounds (dilevalol and carvedilol), three calcium antagonists (amlodipine, felodipine, and diltiazem), an angiotensin-converting enzyme inhibitor (lisinopril), a serotonin antagonist (ketanserin), and low-salt diet as a nonpharmacological treatment in 171 patients with mild to moderate essential hypertension. The results in the treatment groups are compared to the hemodynamic changes seen in 28 hypertensive patients left untreated for 10 years. The patient populations of the different groups were comparable. The invasive hemodynamic technique, including intraarterial blood pressure recording and measurements of cardiac output by Cardigreen, was the same in all studies. While blood pressure remained nearly unchanged in the untreated group, all antihypertensive compounds induced significant and sustained blood pressure reduction both at rest and during exercise. The modest reduction (3-5%) in blood pressure during a low-salt diet was also statistically significant. This review shows the multiplicity of the long-term hemodynamic changes, ranging from a reduction in cardiac output to peripheral vasodilatation, during chronic antihypertensive therapy. In untreated hypertensives, the cardiac output is reduced by 1-2% per year and total peripheral resistance is increased by 2-3% per year. The review also focuses on counterregulatory responses and modify the initial reduction in blood pressure after drug treatment for hypertension. It is concluded that proper understanding of the hemodynamic effects of antihypertensive agents is useful in the selection of the right treatment for specific groups of hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395198     DOI: 10.1007/bf00878508

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  56 in total

1.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1988-05

2.  By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction.

Authors:  M R Law; C D Frost; N J Wald
Journal:  BMJ       Date:  1991-04-06

3.  Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  Eur Heart J       Date:  1990-06       Impact factor: 29.983

4.  The dye dilution method for measurement of cardiac output.

Authors:  P Lund-Johansen
Journal:  Eur Heart J       Date:  1990-12       Impact factor: 29.983

5.  Comparison of long-term hemodynamic effects at rest and during exercise of lisinopril plus sodium restriction versus hydrochlorothiazide in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Am J Cardiol       Date:  1990-02-01       Impact factor: 2.778

6.  Serotonin (5-hydroxytryptamine).

Authors:  I H PAGE
Journal:  Physiol Rev       Date:  1954-07       Impact factor: 37.312

7.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Repeat hemodynamic determinations in borderline hypertension.

Authors:  Y A Weiss; M E Safar; G M London; A C Simon; J A Levenson; P M Milliez
Journal:  Am J Med       Date:  1978-03       Impact factor: 4.965

9.  Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.

Authors:  G Sponer; W Bartsch; K Strein; B Müller-Beckmann; E Böhm
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

10.  The Australian therapeutic trial in mild hypertension. Report by the Management Committee.

Authors: 
Journal:  Lancet       Date:  1980-06-14       Impact factor: 202.731

View more
  5 in total

Review 1.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

2.  Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series).

Authors:  Wei Tan; Krishna Madhavan; Kendall S Hunter; Daewon Park; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

Review 3.  Exercise blood pressure: clinical relevance and correct measurement.

Authors:  J E Sharman; A LaGerche
Journal:  J Hum Hypertens       Date:  2014-10-02       Impact factor: 3.012

Review 4.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 5.  Exercise Hypertension.

Authors:  Martin G Schultz; James E Sharman
Journal:  Pulse (Basel)       Date:  2014-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.